Angioplasty in the Diabetic Patient

Journal of Invasive Cardiology

Volumn 16, Issue 1, 2004, Pages 23-27

  Van Belle, Eric ^a   Chmaït, Akram ^a   Bauters, Christophe ^a   Lablanche, Jean Marc ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Diabetes; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; RAPAMYCIN;

ANGIOPLASTY; BRACHYTHERAPY; CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES MELLITUS; DRUG ELUTING STENT; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; REVIEW;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY STENOSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HUMANS; MALE; PROGNOSIS; RECURRENCE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0347122961     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Davi G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990;322:1769-1774.
2. Sobel BE, Woodcock-Mitchell J, Schneider DJ, et al. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: A potential factor predisposing to thrombosis and its persistence. Circulation 1998;97:2213-2221.
3. Sobel BE. Acceleration of restenosis by diabetes: Pathogenic implications. Circulation 2001;103:1185-1187.
4. The BARI Investigators. Influences of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: The Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1997;96:1761-1769.
5. King SB III, Kosinski AS, Guyton RA, et al. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). J Am Coll Cardiol 2000;35:1116-1121.
6. Kurbaan AS, Bowker TJ, Ilsley CD, et al. Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode (Abstr). Am J Cardiol 2001;87:947-950.
7. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
8. Weintraub WS, Stein B, Kosinski A, et al. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. J Am Coll Cardiol 1998;31:10-19.
9. Detre KM, Guo P, Holubkov R, et al. Coronary revascularization in diabetic patients. A comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1999;99:633-640.
10. Barsness GW, Peterson ED, Ohman EM, et al. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation 1997;96:2551-2556.
11. Rozenman Y, Sapoznikov D, Mosseri M, et al. Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus. A clue to the explanation of the results of the BARI study. Balloon Angioplasty Revascularization Investigators. J Am Coll Cardiol 1997;30;1420-1425.
12. Van Belle E, Abolmaali K, Bauters C, et al. Restenosis, late vessel occlusion and left ventricular function 6 months after balloon angioplasty in diabetic patients. J Am Coll Cardiol 1999;34:476-485.
13. Kip KE, Faxon DP, Dette KM, et al. Coronary angioplasty in diabetic patients. The National Heart, Lung and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996;94:1818-1825.
14. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996;27:528-535.
15. Moreno PR, Murcia AM, Fallon JT, et al. Smooth muscle cell proliferation does not account for restenosis in diabetic patients. Circulation 1996;94;1-619.
16. Van Belle E, Bauters C, Hubert E, et al. Restenosis rates in diabetic patients: A comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation 1997;96:1454-1460.
17. Van Belle E, Ketelers R, Bauters C, et al. Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up: A key determinant of survival in diabetics after coronary balloon angioplasty. Circulation 2001;103:1218-1224.
18. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956-961.
19. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
20. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
21. Bhatt DL, Marso SP, Lincoff AM, et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000;35:922-928.
22. Lincoff AM. Does stenting prevent diabetic arterial shrinkage after percutaneous coronary revascularization? Circulation 1997;96:1374-1377.
23. Van Belle E, Perie M, Braune D, et al. Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients. J Am Coll Cardiol 2002;40:410-417.
24. Serruys PW, Unger F, Crean PA, et al. Arterial Revascularization Therapy Study (ARTS): A randomized trial of stenting in multivessel coronary disease versus bypass surgery: Two-year results. Eur Heart J 2001;22(Suppl):232.
25. Leon M. The Sirius Trial. American Heart Association Scientific Sessions, Chicago, IL, USA, November 16-20, 2002.
26. Regar E, Serruys PW, Bode C, et al. Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): Sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 2002;106:1949-1956.
27. Gruberg L, Waksman R, Ajani AE, et al. The effect of intracoronary radiation for the treatment of recurrent in-stent restenosis in patients with diabetes mellitus. J Am Coll Cardiol 2002;39:1930-1936.
28. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus; Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259.
29. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
30. Clarke P, Gray A, Adler A, et al. UKPDS: UK Prospective Diabetes Study. Cost-effective analysis of intensive blood glucose control with metformine in overweight patients with type 2 diabetes. Diabetologia 2001;44:298-304.
31. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-1887.